CSL Behring

What CSL Behring does

CSL Behring is the largest business unit of CSL Limited (ASX: CSL), a publicly listed Australian biotechnology group that also includes CSL Seqirus (vaccines) and CSL Vifor (iron deficiency and nephrology). The company develops, manufactures, and commercializes plasma-derived and recombinant biotherapies for rare and serious diseases across five therapeutic areas: hereditary bleeding disorders (hemophilia A and B, von Willebrand disease), immunodeficiency and autoimmune diseases, hereditary angioedema, Alpha 1 Antitrypsin Deficiency, and transplant/cardiovascular/respiratory conditions. It is built on three strategic scientific platforms — plasma fractionation, recombinant protein technology, and cell and gene therapy — and operates CSL Plasma, one of the world's largest plasma collection networks, which is vertically integrated such that collected plasma is used solely for CSL Behring's own manufacturing. The company sells into more than 100 countries and is supported by 32,000+ employees at the parent-group level (10,000+ listed under CSL Behring).

The product portfolio spans immunoglobulins, coagulation factors, albumin, and recombinant protein therapies, with HEMGENIX (etranacogene dezaparvovec) as the flagship asset: a one-time gene therapy for hemophilia B priced at $3.5 million per dose, which became the sole commercially available gene therapy in its category after Pfizer discontinued Beqvez in February 2025. Five-year durability data demonstrates sustained factor IX expression and reduced annualized bleeding rates. The newly launched ANDEMBRY extends the immunoglobulin franchise. Manufacturing is anchored by a $1.5 billion Kankakee, Illinois expansion announced March 2026 (completion 2031) and the Project Aurora Plasma Base Fractionation Facility in Broadmeadows, Australia, the 2025 ISPE Facility of the Year Awards (FOYA) Overall Winner.

Revenue is generated through direct enterprise sales to hospitals, specialty pharmacies, and rare-disease treatment centers, with reimbursement negotiated through national payer systems (e.g., the pan-Canadian Pharmaceutical Alliance for HEMGENIX) and outcomes-based contracts with U.S. insurers offering refund guarantees. Parent CSL Limited reported H1 FY2026 group revenue of $8.3 billion, down 4% on constant currency, with net profit down 81% due to $1.1 billion in one-off impairments; a strategic transformation program targets $500–550 million in annual cost savings by FY2028. CSL Behring serves an inherently niche, high-value patient base — U.S. eligibility for HEMGENIX is estimated at approximately 1,000 patients given strict liver-health and anti-AAV antibody criteria — making payer access and treatment-center infrastructure the primary commercial gating factors.

Name

CSL Behring

Legal name

CSL Behring

Website

https://cslbehring.com

Company type

Private

Founded year

1904

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

CSL Behring is the biotherapeutics subsidiary of CSL Limited, developing plasma-derived, recombinant, and gene therapies (including HEMGENIX) for rare diseases such as hemophilia, immunodeficiencies, and hereditary angioedema, serving patients in over 100 countries through specialty treatment centers and payer reimbursement networks.

Ownership category

akta.pro rank

Product category

Plasma-derived Biopharmaceutical Therapies

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Plasma Fractionation & Purification Manufacturing (HLAIAHAI)

akta.pro secondary industries

Plasma-Derived Coagulation Factors (Hemophilia Therapies) (HLAIAHAB), Plasma-Derived Therapeutics (immunoglobulins, albumin, clotting factors) (HLAAAAAI), Plasma-Derived Protease Inhibitors & Complement Modulators (e.g., C1 Esterase Inhibitor) (HLAIAHAF), Plasma-Derived & Blood Products Distributors (HLAIAJAJ), Plasma-Derived Therapy Quality, Safety & Pharmacovigilance (Pathogen Reduction/Testing) (HLAIAHAK), Plasma-Derived Therapy Fill-Finish & Packaging (HLAIAHAJ)

Keywords

• Plasma protein therapies
• Recombinant biotherapeutics
• Gene therapy
• Rare disease treatments
• Immunoglobulin therapies

Headquarters

HQ city

King Of Prussia

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Biopharmaceutical Therapies: CSL Behring generates revenue through the sale of plasma-derived and recombinant biotherapy products for treating rare and serious diseases including bleeding disorders, immune deficiencies, hereditary angioedema, and Alpha 1 Antitrypsin Deficiency.
2. Gene Therapy (HEMGENIX): One-time gene therapy treatment for hemophilia B priced at $3.5 million per dose
3. Plasma Collection and Integration: CSL Behring operates CSL Plasma, one of the world's largest plasma collection networks, which is vertically integrated meaning plasma collected is used solely for manufacturing CSL Behring's life-saving therapies

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels4 records

Core offering

CSL Behring develops, manufactures, and commercializes plasma-derived and recombinant biotherapies for rare and serious diseases, including Hemgenix (a $3.5 million one-time gene therapy for hemophilia B), ANDEMBRY, immunoglobulins, coagulation factors, albumin, and other plasma-derived proteins. The company's offerings are built on three strategic scientific platforms (plasma fractionation, recombinant protein technology, and cell and gene therapy) and are supported by a vertically integrated plasma collection network (CSL Plasma).

Product overview

CSL Behring is a global biotherapeutics company offering a broad portfolio of plasma-derived and recombinant therapies for rare and serious diseases. Their product portfolio centers on treating conditions in immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas. Key products include Hemgenix (a $3.5M one-time gene therapy for hemophilia B) and ANDEMBRY. The company operates across three strategic scientific platforms: plasma fractionation (producing plasma-derived therapies like immunoglobulins and coagulation factors), recombinant protein technology, and cell and gene therapy. CSL Behring also operates CSL Plasma, a vertically integrated plasma collection network, ensuring closed-loop supply from plasma collection to finished therapy delivery across more than 100 countries.

Differentiator

Problem solved

Functional benefit

Brands

• CSL Plasma: One of the world's largest plasma collection networks, vertically integrated with CSL Behring for manufacturing life-saving therapies
• HEMGENIX
• ANDEMBRY

Products and services

• Hemgenix (etranacogene dezaparvovec) Hemgenix is a one-time gene therapy for hemophilia B that delivers a functional copy of the factor IX gene, enabling patients to produce their own clotting factor. Priced at $3.5 million per dose, it is the only FDA-approved commercially available gene therapy for hemophilia B following Pfizer's discontinuation of Beqvez in February 2025, and is supported by five-year durability data showing sustained factor IX levels and reduced annualized bleeding rates. It is administered through hospitals and specialty treatment centers with reimbursement via outcomes-based agreements.
• ANDEMBRY ANDEMBRY is a therapy in CSL Behring's immunoglobulin portfolio, launched as a newly introduced product for the treatment of patients with immunodeficiency and autoimmune diseases. It is part of CSL Behring's broader strategy to expand its immunoglobulin offerings alongside its plasma-derived therapy franchise.
• Plasma-Derived Therapies CSL Behring's broad portfolio of plasma-derived therapies includes immunoglobulins (for primary immunodeficiency and autoimmune diseases including CIDP), coagulation factors (for hemophilia A and B, von Willebrand disease, and fibrinogen deficiency), C1 esterase inhibitor therapies (for hereditary angioedema), Alpha 1 Antitrypsin (for Alpha 1 Antitrypsin Deficiency), and albumin, all produced via advanced plasma fractionation of human plasma collected through the vertically integrated CSL Plasma network.
• Recombinant Protein Therapies Recombinant protein therapies manufactured using DNA-based technology, complementing CSL Behring's plasma-derived portfolio for the treatment of rare and serious diseases across immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas. These therapies reduce dependence on human plasma supply and offer scalable alternatives for select indications.

Named customers2 records

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• pan-Canadian Pharmaceutical Alliance (pCPA)coreChannel Partner/ Reseller/ Distributor · 9 October 2025CSL Behring signed a Letter of Intent with the pan-Canadian Pharmaceutical Alliance for the public reimbursement of HEMGENIX (etranacogene dezaparvovec), the first gene therapy for hemophilia B. This agreement enables provinces outside Quebec to list the therapy on their formularies, with ongoing discussions in Quebec for reimbursement.

Scale indicators6 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Grifols: Grifols is a global leader in plasma-derived therapies and operates one of the largest plasma collection networks (Biomat USA). It directly competes with CSL Behring across immunoglobulins, coagulation factors, and albumin, and is the closest comparable in vertically integrated plasma fractionation.
• Takeda Pharmaceutical (Shire): Through its acquisition of Shire, Takeda operates the BioLife plasma collection network and competes directly with CSL Behring in plasma-derived immunoglobulins and rare disease therapies including hereditary angioedema (Firazyr/TAKHZYRO) and hemophilia products.
• Octapharma: Octapharma is one of the largest privately held plasma fractionators globally, producing immunoglobulins, coagulation factors, and other plasma-derived therapies. It competes head-to-head with CSL Behring in coagulation factors and immunoglobulins worldwide.
• Kedrion Biopharma: Kedrion is a privately held plasma-derived therapeutics company specializing in coagulation factors, immunoglobulins, and rare disease treatments. It is a direct competitor in the plasma fractionation market with comparable product categories to CSL Behring.
• Bio Products Laboratory (BPL): BPL is a UK-based global plasma fractionator producing coagulation factors, immunoglobulins, and albumin. It directly overlaps with CSL Behring's plasma-derived therapy portfolio and targets similar rare disease patient populations.

Emerging players

• BioMarin Pharmaceutical: BioMarin is developing Roctavian, an FDA-approved gene therapy for hemophilia A, and has historically been active in hemophilia and rare disease biotherapeutics. It represents both a competitive gene therapy peer to HEMGENIX and a broader rare-disease platform competitor.
• uniQure: uniQure co-developed HEMGENIX (etranacogene dezaparvovec) with CSL Behring and is a pioneer in AAV-based gene therapies. It is both a partner and adjacent gene therapy peer, with a pipeline that could compete with or extend CSL Behring's hemophilia franchise.

Broad incumbents

• Pfizer: Pfizer previously competed in hemophilia B gene therapy via Beqvez (discontinued February 2025) and operates a broader biotherapeutics portfolio including rare disease assets. It is a broad incumbent in the rare disease and gene therapy space adjacent to CSL Behring.
• Sanofi: Sanofi operates Sanofi Genzyme with a rare disease franchise including enzyme replacement therapies and immunoglobulins (e.g., Hyqvia partnership). As a large pharmaceutical incumbent with plasma-adjacent and rare disease products, it competes with CSL Behring in selected therapeutic areas.
• Novo Nordisk: Novo Nordisk markets NovoSeven (recombinant factor VIIa) and NovoEight (recombinant factor VIII) for hemophilia, plus a broader rare disease portfolio. As a major recombinant coagulation factor competitor, it is a broad incumbent peer whose recombinant strategy could substitute for plasma-derived products.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/cslbehring
• YouTubeyoutube.com/user/CSLGroup
• Facebookfacebook.com/51976781570
• LinkedInlinkedin.com/company/csl-behring
• Instagraminstagram.com/cslbiotechnology

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CSL Behring